Yu Chen

ORCID: 0000-0003-4458-4039
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Immunotherapy and Biomarkers
  • Liver Disease Diagnosis and Treatment
  • Lymphatic System and Diseases
  • Pancreatic and Hepatic Oncology Research
  • Flavonoids in Medical Research
  • Healthcare and Venom Research
  • Lung Cancer Research Studies
  • Nonmelanoma Skin Cancer Studies
  • Traditional Chinese Medicine Studies
  • Liver Disease and Transplantation
  • Cutaneous lymphoproliferative disorders research
  • COVID-19 and healthcare impacts
  • T-cell and B-cell Immunology
  • Immunotherapy and Immune Responses
  • Immune Cell Function and Interaction
  • Chronic Lymphocytic Leukemia Research
  • CAR-T cell therapy research
  • Cutaneous Melanoma Detection and Management
  • Cancer-related Molecular Pathways
  • Metal-Organic Frameworks: Synthesis and Applications
  • Saffron Plant Research Studies
  • Advanced Breast Cancer Therapies
  • Myasthenia Gravis and Thymoma
  • Neonatal and Maternal Infections
  • Long-Term Effects of COVID-19

Tianjin Tianhe Hospital
2025

Tianjin Medical University
2025

China Medical University
2025

Guangxi University
2025

Guangxi University of Chinese Medicine
2025

Montefiore Medical Center
2024

CancerCare
2024

Albert Einstein College of Medicine
2024

Montefiore Einstein Comprehensive Cancer Center
2024

Guangdong Academy of Medical Sciences
2024

Abstract Pancreatic cancer is a highly aggressive malignancy that strongly resists extant treatments. The failure of existing therapies majorly attributed to the tough tumor microenvironment (TME) limiting drug access and undruggable targets cells. formation suppressive TME regulated by transforming growth factor beta (TGF‐β) signaling, while poor response short survival almost 90% pancreatic patients results from oncogenic KRAS mutation. Hence, simultaneously targeting both TGF‐β pathways...

10.1002/smll.201900631 article EN Small 2019-04-29

KRAS mutations are broadly recognized as promising targets for tumor therapy. T cell receptors (TCRs) can specifically recognize mutant neoantigens presented by human lymphocyte antigen (HLA) and mediate responses to eliminate cells. In the present study, we identify two TCRs specific 9-mer KRAS-G12V neoantigen in context of HLA-A*11:01. The TCR-T cells constructed display cytokine secretion cytotoxicity upon co-culturing with varied expressing mutation. Moreover, 1-2C show anti-tumor...

10.1038/s41467-023-42010-1 article EN cc-by Nature Communications 2023-10-12

<h3>Importance</h3> Immune checkpoint inhibitors (ICIs) can elicit durable antitumor responses in patients with non–small cell lung cancer (NSCLC), but only 20% to 25% of respond treatment. As important genes the DNA damage response pathway, comutation tumor protein p53 (<i>TP53</i>) and ataxia-telangiectasia mutated (<i>ATM</i>) may be associated genomic instability hypermutation. However, prevalence of<i>TP53</i>and<i>ATM</i>comutation its association ICIs are not fully understood....

10.1001/jamanetworkopen.2019.11895 article EN cc-by-nc-nd JAMA Network Open 2019-09-20

Aims: To investigate the mechanisms through which Qianlong Shutong Formula (QLSTF) exerts its effects on management of benign prostatic hyperplasia (BPH). Background: BPH is a prevalent condition among older men and poses significant challenges due to limited effectiveness potential side associated with current treatment options. QLSTF, traditional Chinese medicine, has been utilized in BPH; however, mechanism action remains inadequately understood. Objective: This study aimed identify...

10.2174/0113862073336172241220182220 article EN Combinatorial Chemistry & High Throughput Screening 2025-01-02

Background Diffuse panbronchiolitis (DPB) is an uncommon respiratory disorder characterized by the presence of bronchiolitis and persistent inflammation in adjacent tissues, which can be effectively treated with early diagnosis intervention. DPB a rare complication associated thymoma that remains poorly understood, especially when it occurs conjunction acquired cellular immune deficiency. Case presentation We present case patient following thymectomy radiation therapy. A 47-year-old Chinese...

10.3389/fonc.2025.1496693 article EN cc-by Frontiers in Oncology 2025-01-30

Abstract Background The clinicopathological and survival profiles across primary sites in acral melanoma (AM) are still controversial unclear. Methods This is a multi-center retrospective study. Clinicopathological data of AM patients diagnosed between 1 January 2000 31 December 2017 from 6 large tertiary hospitals China were extracted. Chi square tests used to compare basic characteristics sole, palm nail bed. Melanoma-specific (MSS) differences based on compared by log-rank multivariate...

10.1245/s10434-020-08418-5 article EN cc-by Annals of Surgical Oncology 2020-04-06

Abstract Background SETD2 protects against genomic instability via maintenance of homologous recombination repair (HRR) and mismatch (MMR) in neoplastic cells. However, it remains unclear whether dysfunction is a complementary or independent factor to microsatellite instability-high (MSI-H) tumor mutational burden-high (TMB-H) for immunocheckpoint inhibitor (ICI) treatment, little known regarding this type acts differently various types cancer. Methods This cohort study used multidimensional...

10.1186/s12885-023-10920-4 article EN cc-by BMC Cancer 2023-07-21

Ulceration is regarded as an adverse prognostic factor and used together with tumour thickness to subcategorize patients cutaneous melanoma. However, the impact of ulceration in acral melanoma (AM) controversial.To assess AM variability across different Breslow thicknesses clinical stages.A multicentre retrospective study diagnosed between January 2000 December 2017. Differences melanoma-specific survival (MSS) without were assessed using multivariable Cox proportional hazards model log-rank...

10.1111/bjd.21026 article EN British Journal of Dermatology 2022-01-19

Objective: This study aimed to assess the disease conditions of patients with inflammatory bowel (IBD) in Hubei Province during outbreak Coronavirus Disease 2019 (COVID-19) by questionnaire online and guide their self-management this epidemic.Results: A total 102 eligible questionnaires were included. No patient we surveyed reported a diagnosis COVID-19. Our result showed that 67.86% ulcerative colitis (UC) 80.43% Crohn's (CD) remission, 85.29%of had good quality life. Part (21.57%)...

10.18632/aging.103525 article EN cc-by Aging 2020-07-03

Background The pathogenesis of multiple chronic visceral pain syndromes, such as irritable bowel syndrome (IBS), is not well known, and a result current therapies are ineffective. objective this study was to investigate the effect spinal protein kinase M zeta (PKMζ) on sensitivity in rats with IBS better understand inhibitory peptide (ZIP) therapy for pain. Methods Visceral hypersensitivity were produced by neonatal maternal separation (NMS). assessed electromyographic (EMG) responses...

10.1371/journal.pone.0163324 article EN cc-by PLoS ONE 2016-10-24

The role of liver stiffness measurements (LSM) in patients with primary biliary cholangitis (PBC) remains to be further elucidated. To clarify the prognostic LSM and validate "novel concepts" proposed by Baveno VII Working Group. An analysis significance was performed involving 672 patients. ΔLSM/ΔT were independent risk factors for decompensation, transplantation, or liver-related death (primary outcomes, p < 0.001, both). A rule 5 kPa (10-15-20 kPa) could used denote progressively higher...

10.1007/s12072-023-10587-w article EN cc-by Hepatology International 2023-09-19

Abstract Background T‐cell immunoglobulin and immunoreceptor tyrosine‐based inhibitory motif domain (TIGIT) is an immune checkpoint molecule that suppresses CD8 + function in cancer. However, the expression profile functional significance of TIGIT microenvironment lung adenocarcinoma (LUAD) remain elusive. Interleukin (IL)‐15 has emerged as a promising candidate for enhancing mediated tumour eradication. Exploring therapeutic strategies combine IL‐15 with blockade LUAD warranted. Methods We...

10.1002/ctm2.1553 article EN cc-by Clinical and Translational Medicine 2024-01-01

Background Breast cancer-related lymphedema (BCRL) profoundly impacts patients’ quality of life, causing heightened depression, anxiety, and physical limitations. Surgical removal the axillary nodes, combined with radiation therapy, is a significant risk factor for BCRL. Smarter surgery, coupled early detection fostering education, significantly improves BCRL management, promoting timely diagnosis treatment. A prevention program encompassing all these factors can aid in preventing, treating,...

10.3389/fonc.2024.1418610 article EN cc-by Frontiers in Oncology 2024-07-16

Patients with chronic lymphocytic leukemia (CLL) respond well to initial treatment the Bcell lymphoma 2 (BCL2) inhibitor venetoclax. Upon relapse, they often retain sensitivity BCL2 targeting, but durability of response remains a concern. We hypothesize that targeting both and B-cell lymphoma-extra large (BCLXL) will be successful strategy treat CLL, including for patients who relapse on To test this hypothesis, we conducted pre-clinical investigation LP-118, highly potent moderate BCLXL...

10.3324/haematol.2023.284353 article EN cc-by-nc Haematologica 2024-08-08

Genipin-1-β-d-gentiobioside (GG) is a kind of compound extracted from Gardenia jasminoides Ellis. The chemical structure GG similar to that geniposide and has antidiabetic effects. We aimed investigate the efficacy on diabetic nephropathy (DN) in vivo vitro experiments explore its potential mechanism.

10.1093/jpp/rgab041 article EN Journal of Pharmacy and Pharmacology 2021-02-16

Abstract Small cell lung cancer (SCLC) is an aggressive form neuroendocrine carcinoma with limited treatment options and poor prognosis, novel approaches are urgently needed for the of this disease. Bcl-2 Bcl-xl aberrantly expressed in 60-70% SCLC have been considered as promising therapeutic targets SCLC. However, navitoclax (ABT-263), a Bcl-2/Bcl-xl dual inhibitor, demonstrated efficacy while induced sever adverse events, such thrombocytopenia due to platelet toxicity mediated by...

10.1158/1538-7445.am2024-675 article EN Cancer Research 2024-03-22

Abstract Background and Aims The outbreak of Coronavirus Disease 2019 (COVID-19) may affect the disease status patients with inflammatory bowel (IBD). This study aimed to assess IBD in Hubei province by questionnaire online guide self-management during this epidemic. Methods A was designed containing Harvey-Bradshaw Index (HBI), Partial Mayo Score (PMS), short (SIBDQ) distributed within one month traffic control after COVID-19. also included some questions about patients’ self-report...

10.1101/2020.03.25.20043364 preprint EN medRxiv (Cold Spring Harbor Laboratory) 2020-03-27
Coming Soon ...